UPDATE: Citi Downgrades Core Laboratories (CLB) to Sell on Lofty Valuation, Slow Margin Recovery
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
Citi analyst Scott Gruber downgraded Core Laboratories (NYSE: CLB) from Neutral to Sell with a price target of $36.00 (from $30.00).
The analyst comments "We downgrade CLB to Sell and see ~25% downside to our new TP of $36, equivalent to almost a 4.5% yield on our forecast 2022 FCF. CLB's stock is up 80% YTD, having outperformed all of its SMID cap peers and large cap names under our coverage. Yet the outperformance, especially of late, appears overdone as the stock currently trades at one of the lowest 2022 FCF yield within OFS, at ~3.3%. This is within the normal range of CLB historically but we struggle to view such a low yield, both absolute and relative, as still appropriate given a lack of differentiated growth. Thus, we are downgrading CLB to sell on the expectation for near term multiple compression given the catalyst for a weaker than consensus expected 2q21 earnings print and continued modest incrementals in 3q as costs normalize. We initiate a negative catalyst watch into earnings as a result."
Shares of Core Laboratories closed at $47.81 yesterday.
You May Also Be Interested In
- Sands China Ltd. (1928:HK) (SCHYY) PT Lowered to HK$31 at Morgan Stanley
- Computershare Limited (CPU:AU) (CMSQY) PT Raised to AUD17.60 at Morgan Stanley
- Bank Central Asia Tbk (BBCA:IJ) (PBCRY) PT Lowered to IDR36,500 at HSBC
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Comments, Hot Downgrades
Related EntitiesCiti, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!